Last reviewed · How we verify

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

NCT05269381 PHASE1, PHASE2 RECRUITING

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.

Details

Lead sponsorMayo Clinic
PhasePHASE1, PHASE2
StatusRECRUITING
Enrolment132
Start dateThu Mar 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionFri Mar 31 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

United States